Skip to content

Comparison of the number of high quality embryos in patients with polycystic ovary syndrome between early follicular phase long-acting GnRH agonist protocol and GnRH antagonist protocol: a randomized controlled clinical study

Comparison of the number of high quality embryos in patients with polycystic ovary syndrome between early follicular phase long-acting GnRH agonist protocol and GnRH antagonist protocol: a randomized controlled clinical study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045093
Enrollment
Unknown
Registered
2021-04-06
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

Early follicular phase ovarian stimulation protocol group:Gonadotropin
GnRH antagonist protocol group:Antagonist and gonadotropin

Sponsors

The Third Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1.Aged >=20 and <35 years; 2.PCOS patients according to Rotterdam standards; 3.People who are planning to undergo IVF or ICSI in the first or second cycle.

Exclusion criteria

Exclusion criteria: 1.Diagnosed as a patient with abnormal uterine cavity morphology (confirmed by three-dimensional ultrasound or hysteroscopy), including uterine malformations (mediastinal uterus, unicornuate uterus, double uterus), submucosal uterine fibroids or intrauterine adhesions; 2.Patients planning PGD/PGS assisted pregnancy; 3.The patient has hydrosalpinx that can be seen under B ultrasound; 4.The patient has a history of recurrent miscarriage (the previous 2 or more pregnancies are lost, excluding biochemical pregnancy); 5.Any chromosome of both spouses Abnormal; 6.Severe endometriosis, organic ovarian disease, and patients with a history of ovarian surgery; 7.There are contraindications for assisted reproductive technology and pregnancy or diseases that have a clear effect on pregnancy: including no Controlled hypertension, heart disease with clear symptoms, uncontrolled diabetes, undiagnosed liver and kidney disease or liver and kidney dysfunction, severe anemia; history of past venous thrombosis, history of pulmonary embolism or cerebrovascular events, history of malignant tumors, Suspected malignant tumor, undiagnosed abnormal uterine bleeding.

Design outcomes

Primary

MeasureTime frame
The number of high quality embryos;

Secondary

MeasureTime frame
The number of oocytes retrieved;The number of MII oocytes;The number of mature oocytes;The number of 2PN embryos;The rate of 2PN fertilization;The number of 2PN cleavage;The number of available embryos;The rate of high-quality embryos;The number of blastocysts;The rate of blastocyst formation;The clinical pregnancy rate;The miscarriage rate;The preterm delivery rate;The live birth rate;The cumulative live birth rate;

Countries

China

Contacts

Public ContactGuan Yichun

The Third Affiliated Hospital of Zhengzhou University

lisamayguan@126.com+86 13608695579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026